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A DNA aptamer recognising a 
malaria protein biomarker can 
function as part of a DNA origami 
assembly
Maia Godonoga1,2, Ting-Yu Lin1,†, Azusa Oshima3, Koji Sumitomo3, Marco S. L. Tang4, 
Yee-Wai Cheung4, Andrew B. Kinghorn4, Roderick M. Dirkzwager4, Cunshan Zhou5, 
Akinori Kuzuya6, Julian A. Tanner4 & Jonathan G. Heddle1,7
DNA aptamers have potential for disease diagnosis and as therapeutics, particularly when interfaced 
with programmable molecular technology. Here we have combined DNA aptamers specific for the 
malaria biomarker Plasmodium falciparum lactate dehydrogenase (PfLDH) with a DNA origami scaffold. 
Twelve aptamers that recognise PfLDH were integrated into a rectangular DNA origami and atomic 
force microscopy demonstrated that the incorporated aptamers preserve their ability to specifically 
bind target protein. Captured PfLDH retained enzymatic activity and protein-aptamer binding was 
observed dynamically using high-speed AFM. This work demonstrates the ability of DNA aptamers to 
recognise a malaria biomarker whilst being integrated within a supramolecular DNA scaffold, opening 
new possibilities for malaria diagnostic approaches based on DNA nanotechnology.
Aptamers, the nucleic acid equivalent of antibodies, are synthetic single stranded DNA or RNA oligonucleotides 
capable of specific, high affinity binding to a target. This capability is attributed to their folding into particular 
three-dimensional configurations exploiting intermolecular binding forces such as hydrogen bonds, electrostatic 
forces and Van Der Waals forces. Aptamers were first developed in 1990 as short RNA strands with specific bind-
ing affinities via the systematic evolution of ligands by exponential enrichment (SELEX) technique1,2. Subsequent 
development has also allowed the production of DNA aptamers. Aptamers have had some success as therapeu-
tic agents3 and are increasingly targeted for biosensing applications thanks to their advantages in size, stability, 
reproducibility and cost, especially when compared with antibodies4. For sensing applications, aptamers can be 
labeled with a number of useful reporter molecules such as fluorophores, gold nanoparticles, quantum dots and 
molecular beacons5. The fact that aptamers can be regenerated through simple denaturation and renaturation 
steps also makes DNA an ideal material for reusable sensors6. Aptamers have been integrated into larger scale 
DNA structures including aptamers for single chain antibodies7 and thrombin8 (for which the high resolution 
structure is known)9.
Recently a diagnostic aptamer (utilised in this study) was developed to detect the malaria biomarker 
Plasmodium falciparum lactate dehydrogenase (PfLDH). The crystal structure of the aptamer-protein complex 
was solved at 2.1 Å resolution and revealed two aptamers binding per tetrameric PfLDH10 (Fig. 1a). The aptamer 
was found to bind with a unique distorted hairpin structure comprising a B-helical stem, an asymmetric internal 
loop and an apical loop. Clear electron density was observed for the first 27 bases in the asymmetric unit of both 
aptamers, while the last eight bases at the 3′ end displayed no electron density beyond the hairpin structure, an 
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effect ascribed to the distortion of the aptamer tail10. The complex interaction was attributed to the extensive salt 
bridges between each aptamer and the cofactor binding sites of protein subunits10. The aptamer was subsequently 
demonstrated as being capable of detecting PfLDH in blood samples11. It is hoped that these aptamers can be 
developed as useful actuators: components of “smart” malaria diagnostic tools. To this end, integration of the 
aptamers into DNA origami is being investigated.
The DNA origami method introduced by Rothemund12 revolutionised the field of DNA nanotechnology and 
has allowed for exquisite nano-architectures to be achieved with relative experimental simplicity. The method uti-
lises M13 bacteriophage single-stranded genomic DNA as a template strand, which can be molded into a required 
2D or 3D shape using approximately 200 complementary “staple” strands. Functionally, DNA origami can form 
the basis of single molecule analysis systems13 and has potential as a way of arraying enzymes, which may be 
advantageous for detector systems. This has been demonstrated using horseradish peroxidase, glucose oxidase14 
and alkaline phosphatase15 with such methods having recently been investigated for biomedical applications16 
and as a basis for sensing systems17. DNA origami can also be used to construct programmable nano-robots that 
are able to produce a measurable response in the presence of specific (often disease-related) molecular signals. A 
primary example was demonstrated in 2012 by Douglas et al.18 whereby a DNA origami nano-robot was used to 
deliver antibody fragments to cells.
Sharing the same construction material (DNA), aptamer and DNA origami technologies can easily be linked 
together and aptamers have previously been incorporated into DNA origami8,18,19, although few with clear medi-
cal applicability. Nevertheless, aptamers do have significant potential in the development of smart, DNA-origami 
based medical sensors. These may be devices that utilise aptamers to detect disease-associated molecules and 
execute a response based on their presence. Aptamers can fulfill this role due to their ability to trigger large scale 
conformational changes in molecular devices upon specific binding of target molecules as was demonstrated in 
the nano-robot of Douglas et al.18 where, crucially, opening to deliver the payload was actuated by DNA aptamer 
switches. This provides a general blueprint for diagnostic systems that could function in an analogous manner: 
releasing dyes or other easily detectable molecules in response to binding of disease-related signals to aptamer 
switches.
We envisage a malaria detecting system consisting of a nanometric DNA origami capsule containing a sig-
naling molecule. The capsule opens and releases the signal only in the presence of a malaria specific molecule 
(PfLDH, a known, important diagnostic target for malaria20,21). This is achieved using aptamers for PfLDH that 
form logic gates integrated into the origami structure. Such a device may be useful as malaria is a major threat to 
human health and was responsible for over 500,000 deaths in 201322. Resistance to existing drugs including the 
currently most effective treatments have been reported23,24 and while progress has been made in vaccine develop-
ment, a universally applicable vaccine seems a distant prospect at present. The effectiveness of existing and future 
treatments is improved with early and accurate diagnosis, meaning that the development of increasingly sensitive, 
robust and sophisticated diagnostic systems is desirable.
As particular aptamers have unique characteristics, each aptamer module incorporated into DNA origami 
must be assessed to ensure that it maintains its active binding conformation. In the current study we describe 
Figure 1. Design and assembly of AM-DNA origami. (a) The crystal structure of PfLDH with two aptamers 
bound (pdb 3ZH210). PfLDH is shown in cartoon format with each monomer coloured a different colour. 
Aptamer strands are shown in stick format and coloured red. (b) DNA origami is made by mixing the M13 DNA 
strand with staple strands. 12 staple strands were modified with additional sequences (red) corresponding to 
a linker sequence followed by the aptamer sequence. (c) After annealing, the rectangular DNA origami was 
formed with the 12 aptamer sequences protruding from the surface (red). (d) PfLDH (grey circle) is mixed  
with the modified DNA origami. (e) Immobilisation of PfLDH on the rectangular DNA origami surface.  
(f) Schematic of DNA origami strand arrangement. The M13 template is shown in black and the staple strands 
are shown in red. Red staple strands on the right of the structure are those which were modified by addition of 
the aptamer sequences while strands 127, 129, 150, 151, 152, 153 are the index staples. Staple strands are named 
as in Table 1.
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the production of a rectangular DNA origami scaffold integrated with the PfLDH-binding DNA aptamer10. We 
demonstrate that upon integration with DNA origami, the aptamers are able to retain the ability to bind specifi-
cally to PfLDH. This is the first attempt to use PfLDH in conjunction with DNA origami as an initial step towards 
the goal of more complex “smart” malaria detection/treatment devices.
Results and Discussion
Design of modified DNA origami and aptamer strands. We based our DNA origami template on a 
standard rectangle design25 (see supplementary materials for sequences) and employed aptamer sequences known 
to bind to PfLDH, whose structure and interaction with target protein are known in unprecedented detail10. In 
order to incorporate these aptamers into DNA origami, a staple sequence complementary to part of the M13 DNA 
origami template strand was added at the 5′ end of the aptamer. We produced 12 different modified aptamers 
containing 12 staple sequences complementary to M13 DNA at positions that formed a linear pattern along one 
edge of the DNA rectangle (Fig. 1, Table 1). Previously, a strong position-dependent hybridisation effect was 
ascribed to electrostatic repulsion between the target and the underlying tile; as well as weaker steric hindrance at 
the edge of the tile and stronger repulsion between probes in the middle of the tile25. By locating aptamers at the 
edge of the DNA origami we expect to increase protein accessibility. To further increase flexibility of the aptamer, 
a linker sequence, consisting of 20 thymidines was included between the staple and aptamer sequences.
When the aptamer-modified (AM) DNA origami is on a mica surface it is possible that the aptamer sequences 
may lie on the surface of the DNA origami facing the mica and hence not visible during atomic force microscopy 
(AFM) analysis. Although Voigt et al. reported that 90–95% of chemically modified DNA origamis had modifica-
tions that were facing the solution26, for some origami structures we included an index sequence to provide ori-
entation. The index consisted of six aptamers located on the left side of the DNA origami as previously described 
by Ke et al.25 (see Table 1, Fig. 1f).
Aptamer strands attached to DNA origami staples retain PfLDH-binding specificity. For even-
tual application as part of a diagnostic system for malaria, AM-origami should bind PfLDH but not the human 
homolog (hLDH). In order to test if the modified aptamers were able to retain binding specificity for PfLDH, we 
carried out electrophoretic mobility shift assays (EMSA) in the presence of increasing concentrations of either 
PfLDH or hLDH (see Supplementary Figs S1–S13 (one example of which is shown in Fig. 2) and Table 2). The 
Aptamer ID Sequence
76 TATCACCGTACTCAGG AGGTTTAGCGGGGTTT TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
77 TGCTCAGTCAGTCTCT GAATTTACCAGGAGGT TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
79 TGAGGCAGGCGTCAGA CTGTAGCGTAGCAAGG TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
81 CCGGAAACACACCACG GAATAAGTAAGACTCC TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
83 TTATTACGGTCAGAGG GTAATTGAATAGCAGC TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
85 CTTTACAGTTAGCGAA CCTCCCGACGTAGGAA TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
87 TCATTACCCGACAATA AACAACATATTTAGGC TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
89 AGAGGCATAATTTCAT CTTCTGACTATAACTA TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
91 TATGTAAACCTTTTTT AATGGAAAAATTACCT TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
93 GAGCAAAAACTTCTGA ATAATGGAAGAAGGAG TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
95 CGGAATTATTGAAAGG AATTGAGGTGAAAAAT TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
97 CTAAAGCAAGATAGAA CCCTTCTGAATCGTCT TTTT TTTT TTTT TTTT TTTT CTGGGCGGTAGAACCATAGTGACCCAG CCGTCTAC
127 CCAAATCACTTGCCCT TCCTCTTTTGAGGAACAAGTTTTCTTGT GACGAGAACGCCAAAA
129 AAACGAAATGACCCCC TCCTCTTTTGAGGAACAAGTTTTCTTGT AGCGATTATTCATTAC
150 ACGAGTAGTGACAAGA TCCTCTTTTGAGGAACAAGTTTTCTTGT ACCGGATATACCAAGC
151 AGTAATCTTAAATTGG TCCTCTTTTGAGGAACAAGTTTTCTTGT GCTTGAGAGAATACCA
152 GCGAAACATGCCACTA TCCTCTTTTGAGGAACAAGTTTTCTTGT CGAAGGCATGCGCCGA
153 ATACGTAAAAGTACAA TCCTCTTTTGAGGAACAAGTTTTCTTGT CGGAGATTTCATCAAG
Table 1. Sequences of the 12 aptamer staple strands and the 6 index staple strands. The aptamer staple 
strands (76, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97) were modified to include the sequence of the aptamer 
previously reported to bind to PfLDH. Aptamer sequences are shown in italics. The index staple strands are 127, 
129, 150, 151, 152, 153. Index modification sequences are shown in bold.
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results show that all strands retain the ability to bind to PfLDH with typical apparent Kds (fitted with a simple 1:1 
ligand binding equation) of several hundred nM per subunit. These values are higher than the previously reported 
Kd of ∼ 60 nM for unmodified aptamers10, although it must be noted that the earlier results were carried out 
under different experimental conditions. The presence of non-aptamer sequences attached to the aptamer strands 
is likely responsible for the observed decrease in affinity of the aptamer for its target. Non-interacting sequences at 
the termini of aptamers have previously been shown to result in a decreased affinity for their targets, likely due to 
additional unwanted interactions27. Significantly, none of the modified aptamers tested were able to bind to hLDH 
(Supplementary Fig. S13), in agreement with previous results10.
Addition of the aptamer sequence to staple strands at different positions on the origami was also investigated 
(see Supplementary Fig. S14, Supplementary Table S2). These sequences also showed an ability to bind to PfLDH 
(Supplementary Fig. S15, Table S2) with similar affinities, except for strand 87 which showed weak binding 
(Supplementary Fig. S15a, Table S2) and strand 121 which showed no binding (Supplementary Fig. S15e, Table S2). 
Both of these sequences consisted of a central rather than terminal aptamer sequence, flanked at both 5′ and 3′ 
ends by staple sequences. It is likely that these flanking sequences inhibited the specific interactions required for 
recognition of the binding site by the aptamer.
PfLDH-binding AM-staples are able to integrate into a DNA origami structure. Next, we tested 
if the AM-staple strands could integrate into the rectangular DNA origami structure. The modified strands 
were added to the rectangular DNA origami mix, which was annealed according to a standard protocol28. The 
resulting structures were observed using AFM (Fig. 3). Comparison of the DNA origamis with and without 
AM-staple strands show similar rectangle shapes but where AM-strands were included, a linear area of raised 
height (approx. + 2 nm) is visible near one edge of the rectangle at the expected position, confirming the presence 
of the active aptamer strands. All DNA origamis had at least one discernible aptamer, however, the maximum 
number of height peaks varied considerably and was often less than 12 (see also Supplementary Fig. S16). These 
Figure 2. EMSA of aptamer binding to PfLDH: (a) Example of an EMSA for aptamer strand 87 (25 nM) 
binding to PfLDH (0–2500 nM calculated as tetrameric concentration). UB: unbound DNA; B: Bound DNA; 
MB: multiply bound DNA. (b) Binding curve for the gel in (a).
Aptamer ID Kd (nM)
76 965 + /− 265
77 726 + /− 186
79 826 + /− 300
81 970 + /− 254
83 1090 + /− 183
85 713 + /− 161
87 878 + /− 154
89 750 + /− 95
91 984 + /− 177
93 647 + /− 128
95 846 + /− 161
97 760 + /− 126
Table 2. Apparent Kds of PfLDH binding to each aptamer as determined from EMSA.
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could represent the total number of aptamers (i.e. some AM-staples did not integrate into the origami structure), 
or may be due to aptamer-aptamer interaction, resulting in two aptamers appearing as a single structure in AFM. 
This is quite feasible given their partially complimentary sequences and the fact that they are located on adjacent 
double strands and hence separated by only approximately 5 nm.
PfLDH binds specifically at predefined locations to AM-DNA origami. AFM imaging of AM-DNA 
origami after mixing with hLDH showed no binding of the protein (Fig. 4a,b). In contrast, PfLDH bound spe-
cifically to the areas of the DNA origami rectangle corresponding to the location of aptamers, and was visible as 
a ~5 nm increase in height (Fig. 4c,d). Other areas of the DNA origami rarely showed any evidence of protein 
binding, even with protein concentrations as high as 1000 nM, presumably due to electrostatic repulsion between 
the protein (pI 7.12) and the phosphate backbone of the DNA. Most DNA origamis were successfully decorated 
with one or more proteins: In a sample of 100 AM-origamis in the presence of excess PfLDH no examples lacking 
bound protein were observed (Fig. 4e). This apparent high yield for protein-bound AM-origami may be expected 
based on Kd calculations from EMSA experiments. Over repeated observations of large numbers of samples we 
did observe occasional instances of AM-origami with no protein bound, as may be expected thermodynamically 
and which could also be due to a minority of origamis that may lie with their modified surfaces facing the mica 
surface.
Analysis of AM-origamis with PfLDH bound using static AFM (Fig. 4e) showed little evidence for binding of 
more than four proteins, suggesting that the number of proteins that can bind is limited by protein diameter and/
or that each protein may bind simultaneously to two aptamers. This is consistent with the fact the PfLDH tetramer 
is approximately 9 nm in diameter while the 12 equally spaced aptamers are arranged across the ~60 nm width 
of the origami rectangle. Some variability in the apparent diameter of proteins is evident and this may be due to 
occasional binding of proteins as monomers to single aptamers, and, indeed under high speed AFM we were able 
to observe dissociation of the PfLDH tetramer into monomers (Supplementary Movie File M1).
To test the limits of detection, we carried out the experiments with lower concentrations of PfLDH (750 nM 
and 500 nM, Supplementary Figs S17 and S18 respectively). Results indicated that binding could still be 
Figure 3. AFM images of AM-DNA origami rectangles in the absence of protein. (a) Two DNA origami 
rectangles are visible with a column of discrete raised areas corresponding to the position of aptamers. Paths 
used for height profile measurements lie between the pink (“B”) and blue (“A”) arrowheads. (b) Height profile 
plot taken from the height profiles marked in (a). Peaks corresponding to the position of the aptamer-modified 
strands are clearly visible. (c) A higher magnification image analyzed in the same way as (a) and showing 
another DNA origami rectangle with four clear aptamer peaks. (d) Height profile plot taken from the height 
profiles marked in (c).
www.nature.com/scientificreports/
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observed at protein concentration as low as 500 nM (See Supplementary Fig. S18). By comparison, in vivo con-
centrations have been reported as spanning the range 0 ng/mL –22,387.2 ng/mL (mean ± standard deviation 
3,917.5 ± 6,120.9 ng/mL) in patient samples29. The relatively high lower limit we report in this work is consistent 
with EMSA findings (Table 2, Fig. 2) and may also be due to the presence of excess staple strands. We attempted 
to remove these before addition of protein via a range of membrane purification techniques. However, these 
resulted in production of origami structures devoid of aptamers, presumably due to an unfavourable reaction of 
the protruding aptamer with the membrane surface.
Figure 4. AFM images of AM-DNA origami in the presence of hLDH or PfLDH. (a) Two modified DNA 
origamis in the presence of hLDH. Paths used for height profile measurements lie between the pink (“B”) 
and blue (“A”) arrowheads. (b) Height profile plot taken from the height profiles marked in (a). Each origami 
appears to have two distinct height maxima corresponding to positions of aptamers. (c) A modified DNA 
origami in the presence of PfLDH. Paths used for height profile measurements lie between the blue (“C”) 
arrowheads. (d) Height profile plot taken from the height profiles shown in (c) show a large increase in height 
due to bound protein. (e) Analysis of PfLDH binding to AM-DNA origami showing the percentage of measured 
AM-DNA origamis containing the indicated number of bound PfLDH enzymes after incubation with an excess 
of enzyme (n = 100, mean = 3.5, std. dev. = 0.9).
www.nature.com/scientificreports/
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We also tested an alternative DNA origami-PfLDH binding procedure. In this case, protein was bound to the 
aptamer prior to integration into the DNA origami structure, a method that allows for protein-aptamer binding 
in conditions that may not be compatible with DNA origami formation and allows interchangeable aptamer 
modules to be swiftly incorporated with a universal, premade DNA origami “chassis”. In this two-step assembly 
process, the first step comprised of incubating the 12 modified aptamer strands with PfLDH, while annealing the 
remaining staples with the M13mp18 ssDNA backbone as previously. In the second step, the incubated aptamer 
strand-protein assembly was mixed with the partially folded DNA origami and re-annealed (from 37 °C) to allow 
the DNA origami structures to self-assemble fully. AFM analysis showed that binding of PfLDH onto the DNA 
origami surface was successfully achieved using this stepwise addition reaction with results comparable to the one 
step process (Supplementary Fig. S19).
Centrifugation removes unbound protein and promotes protein-mediated intra-origami inter-
action. To decrease the presence of background noise in AFM images due to unbound protein, we carried out 
an ultracentrifugation step (see Experimental Procedures). The results (Fig. 5a–c) showed that this was successful 
in removing the majority of unbound protein from the sample. It also resulted in greater aggregation of individual 
origami rectangles, apparently mediated by protein-protein interactions between bound proteins.
In order to probe stoichiometry of binding we produced DNA origamis with 4 rather than the maximum 12 
aptamers. Modified aptamers 76, 81, 89 and 97 (Fig. 1f) were retained while the remaining modified aptamers 
were replaced with non-modified counterparts. PfLDH-bound origamis were prepared using the centrifugation 
step as described above. The results showed that many origamis aggregated, making clear counting difficult in the 
Figure 5. Effects of centrifugation and blood plasma. (a–c) Centrifugation of modified origamis constructed 
using 12 aptamers in the presence of PfLDH resulted in a significant decrease in the amount of unbound protein 
while aptamer-bound protein remained. Centrifugation also promoted aggregation of origami structures, 
apparently via protein-protein interactions resulting in (b) dimerisation or (c) larger aggregates (indicated 
by arrows). (d) Presence of blood plasma has little effect on AM-DNA origami integrity or protein binding 
ability. Linear arrangements of PfLDH are clearly visible and some aggregation occurs due to protein-protein 
interaction as a result of centrifugation.
www.nature.com/scientificreports/
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majority of cases. However, the analysable origamis showed fewer proteins bound compared to the 12-aptamer 
version, typically no more than two (Supplementary Fig. S20). This could be due to each PfLDH protein binding 
to two aptamers, one for each binding site. The separation between aptamer binding positions in the case of 
the 4-aptamer origami is 15–20 nm, with the linker separating the beginning of the aptamer sequence from the 
origami surface being 20 bases, while the separation between aptamer binding sites within a single PfLDH (as 
measured between K106 residues of monomers A and C10) is approximately 9 nm, which is also the approximate 
overall diameter for the protein.
High-Speed AFM reveals dynamics of PfLDH binding to modified DNA origami. In order to gain 
insight into the dynamics of PfLDH binding to AM-DNA origami we carried out high-speed AFM experiments. 
We were able to view PfLDH-bound modified DNA origami, without protein bound (Supplementary Movie 
Files M2, M3) and with protein bound (Supplementary Movie Files M4-M6) including instances where binding/
unbinding of protein is visible (Fig. 6, Supplementary Movie Files M5-M6). Overall, bound samples under these 
conditions appeared stable, without rapid on/off rates.
DNA aptamers are able to bind PfLDH in the presence of blood plasma. Aptamer-operated DNA 
origami diagnostics for medical use may have to function in the presence of biological fluids. Therefore we tested 
the ability of aptamers incorporated into DNA origami to bind to PfLDH in the presence of human blood plasma. 
Although the densely packed double helical nature of the DNA origami is expected to be resistant to digestion by 
Figure 6. HS-AFM shows dynamics of interaction between AM-origami and PfLDH. Four frames from 
HS-AFM analysis of AM-origami in the presence of PfLDH (see Supplementary Movie File M5) are shown with 
time points indicated in seconds. At 1 s, a single AM-origami is visible with one PfLDH (indicated by white 
arrow) attached to the aptamer-modified region. At 35 s a second PfLDH (indicated by white arrow) binds to the 
region and both proteins remain in place beyond 71 s (see Supplementary Movie File M5).
www.nature.com/scientificreports/
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nucleases30, the aptamers protrude from the origami surface and so could potentially be more vulnerable. Plasma 
was added to solutions containing AM-DNA origami and PfLDH and analysed using AFM (Fig. 5d). The pres-
ence of plasma had little effect on the integrity of the DNA origami, in agreement with previous studies showing 
that DNA origami is stable in cell lysate31 and is viable in living animals32,33. We also found that the presence of 
plasma had no effect on the ability of the aptamers integrated into DNA origami to bind to PfLDH, consistent 
with previous reports for the original aptamer alone11.
PfLDH bound to DNA origami retains enzymatic activity. PfLDH has a well-characterised enzyme 
activity that can easily be detected. The ability to localise and concentrate this activity to specific, defined regions 
of programmable nanodevices and structures could be useful in nanometric detectors. DNA aptamers specific to 
PfLDH have previously been shown to offer the ability to detect the protein in blood samples when coupled with a 
colorimetric assay11. To test if PfLDH similarly retained activity after binding to AM-DNA origami, we separated 
bound sample from unbound protein using ultracentrifugation. We collected fractions at different depths from 
the centrifuged sample and tested for lactate dehydrogenase activity. The results (Fig. 7a) showed that activity was 
highest in the fraction that sedimented most (fraction 30). The same fraction tested in AFM prior to enzymatic 
assay showed protein bound to AM-DNA origamis with little evidence of free protein (Fig. 5d). Comparison to 
other fractions with a lower PfLDH activity showed a similar result but with significantly fewer complexes present 
(Supplementary Fig. S21). Analogous enzyme activity experiments but with the addition of human blood plasma 
showed similar results (Fig. 7b) where, for fraction 30, enzyme activity was retained at a 2–3 fold lower level com-
pared to absence of plasma (Fig. 7a).
Conclusions
We have produced a new DNA origami that incorporates a well-defined aptamer able to specifically bind to 
PfLDH, whose structure is known with Angstrom level precision. This is the first attempt to incorporate a 
malaria-detecting molecule onto a DNA origami scaffold.
The resulting AM-DNA origami is stable and PfLDH binds specifically at aptamer positions with the stoi-
chiometry of binding limited by the size of the protein complex, with a likelihood of two aptamers binding per 
protein complex. The resulting structures are stable under a range of conditions including in the presence of 
human blood plasma. Under high-speed AFM conditions, stable protein-AM-origami binding is observed and 
protein monomers, which may also be capable of aptamer-binding, are readily formed. The bound proteins retain 
enzymatic activity, consistent with the crystal structure10 which shows that the aptamer binding does not block 
the substrate binding site of PfLDH.
A well-characterised aptamer specific to PfLDH could be utilised to actuate a sophisticated DNA origami 
malaria diagnostic device and this work is a first step towards that goal. For example, DNA origami cubes and 
barrels18,34 some of which have been shown able to carry cargo are operated by aptamer “keys”18. By using PfLDH 
aptamers in such systems, they could be adapted to carry signal molecules such as fluorescent dyes that are 
released in the presence of PfLDH when exposed to samples from infected patients. Before such a complex sys-
tem is constructed, the ability of the aptamer to retain specific PfLDH binding activity when incorporated into 
an origami system must be demonstrated. In this work we have shown that such specific binding capability is 
retained when the aptamer is integrated into an origami, providing that it has a flanking staple sequence at only 
one rather than both termini.
The results of these experiments will allow further development of origami systems actuated by 
PfLDH-binding aptamers. A DNA origami container is envisaged which will release easily detectable signal mol-
ecules from a cavity in the presence of PfLDH.
Experimental Procedures. Materials. M13mp18 single stranded DNA was purchased from Takara Bio 
Inc. All 226 staple strands and the additional modified 12 aptamer strands were acquired in powder form from 
Operon (Japan) and diluted to 50 μ M with TE buffer and used without further purification. PfLDH and hLDH 
were produced as described previously10.
DNA origami assembly. A rectangular-shaped DNA origami structure (~90 × 60 nm) was assembled from a 
7.2 kilobase viral M13mp18 single-stranded DNA and 226 staple strands in a buffer containing 1× TAE/Mg2+ 
(40 mM Tris, 20 mM acetic acid, 2 mM EDTA, 12.5 mM magnesium acetate, pH 8). Details of the sequence designs 
of the staple strands are included in the Supplementary Information (Table S1). The concentrations used for the 
study were 12 nM of viral genome scaffold and a fivefold molar excess of staples. The relevant non-modified staple 
strands were replaced with modified counterparts (either AM or index strands) at the same concentration.
DNA mixtures were annealed using a PCR machine (BioRad DNA Engine) at the following settings: for the 
one step assembly and 1st annealing: 90 °C for 10 min, with a subsequent temperature decrease of 1 °C/min until 
25 °C; for the two step assembly and 2nd annealing (re-annealing): 37 °C for 10 min followed by a decrease of 
1 °C/min until 25 °C, repeated five times.
Electrophoretic mobility shift assay. The aptamer strand-protein binding assay was performed by incubating a 
fixed concentration of aptamer staple (25 nM) with varying concentrations of PfLDH protein (0 nM–2500 nM) in 
25 mM Tris-HCl containing 100 mM NaCl, 20 mM imidazole at pH 7.5 and allowed to incubate at 25 °C for 1 h. 
Samples were resolved using a 12% non-denaturing polyacrylamide (37.5:1) gel with a 5% stacking gel layer. 
Samples were loaded for analysis with 20 ng of aptamer in each lane and run at 80 V, 8 °C for 4 h. The gels were 
subsequently stained with SYBR Gold for 25 min and visualised on a UVP Benchtop (2UV Transilluminator) at 
302 nm. Gels were analyzed by ImageJ35 by measuring the change in the intensity of the unbound DNA band. 
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Data was subsequently fitted using a 1:1 ligand binding equation equivalent in form to the Michaelis-Menten 
equation.
Origami-PfLDH complexes. AM-DNA origami (12 nM) was mixed with PfLDH protein (1000 nM) in 25 mM 
Tris-HCl containing 100 mM NaCl, 20 mM imidazole at pH 7.5 and allowed to incubate at 25 °C for 1 h. The 
resulting DNA origami-PfLDH complexes had a final concentration of ~8.6 nM.
Origami-plasma complexes. Human plasma (Sigma Aldrich) was reconstituted in 1 ml of deionised water. 
Aliquots ranging from 1 μ l to 40 μ l were incubated with both DNA origami alone and DNA origami – protein 
complexes to make up a total of 100 μ l of sample, at 25 °C for 1 h. The plasma containing DNA origami samples 
were further purified by rate-zonal centrifugation.
Purification by rate-zonal centrifugation. DNA origami-protein complexes were purified from excess staples, 
unbound protein and human plasma using a glycerol gradient through rate-zonal centrifugation according to 
the method reported previously36. Quasi-continuous glycerol gradients between 45–15% were prepared in 5 ml 
ultracentrifuge tubes, by overlaying seven layers of glycerol solution (45% at the bottom, 700 μ l per layer, 5% 
concentration decrease per layer) and left overnight at 4 °C. Samples (100 μ l each) containing 10% glycerol were 
loaded onto the gradients and centrifuged (Beckman Optima Max ultracentrifuge) at 50000 rpm for 2 h at 4 °C 
via a swinging –bucket rotor (MLS-50). Subsequently, 30 fractions equal in volume were collected and visualised 
under AFM, with aliquots being used for the enzymatic assay.
Enzymatic assay. PfLDH-catalysed conversion of lactate to pyruvate was spectrophotometrically determined by 
following the reduction of NAD+ at 340 nm. 90 μ l of assay mixture containing 2 mM NAD+ (Sigma-Aldrich) and 
71 mM sodium lactate (Sigma-Aldrich) in phosphate buffered saline (PBS) was incubated with an aliquot of the 
post rate-zonal centrifugation fractions (10 μ l) in a 96-well plate at 25 °C. The change in absorbance was recorded 
every 10 min using a microplate reader (SpectraMax M2, Molecular Devices, CA, USA).
AFM imaging. DNA structures were imaged by AFM. Subsequent to annealing and incubation, an aliquot 
(1–2 μ l) of sample was deposited onto the surface of a freshly cleaved mica with 9.9 mm diameter (Agar Scientific, 
Figure 7. Enzymatic activity of post-ultracentrifugation fractions of AM-DNA origami incubated with PfLDH 
and without (a) or with (b) the addition of human blood plasma. Fraction number refers to distance migrated 
during centrifugation with fraction 19 being less dense than fraction 20 and so on. In both a and b symbols are 
as follows: ◆ Fraction 19, ∇ Fraction 20,  Fraction 21, × Fraction 22,  Fraction 23, • Fraction 24, + Fraction 
25, − Fraction 26, ○ Fraction 27, ◆ Fraction 28,  Fraction 29, △ Fraction 30.
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UK) and left to adsorb for 5 min, followed by the addition of 50 μ l of HEPES/Mg2+ buffer (40 mM HEPES, 10 mM 
NiCl2, 12.5 mM magnesium acetate, pH 7.6). The AFM used was a Multimode-AFM with NanoScope5 con-
troller (Bruker Corp., CA, USA). Samples were imaged using a micro cantilever with spring constant ~0.1 N/m 
(BL-AC40TS-C, Olympus, Japan) at a scan rate of 1.95 Hz in peak force tapping mode in fluid.
High speed AFM. Additional imaging was performed by High Speed AFM (HS-AFM) at Kanazawa University. 
The tips used (BL-AC10DS or BL-AC7DS-KU2, Olympus, Japan) were made of amorphous carbon and were each 
sharpened prior to use through a combination of plasma etching and electron-beam deposition. Imaging was 
performed as described previously37.
Analysis of formed DNA origamis. For DNA origami including aptamers but not protein, AFM results were 
examined which allowed the number of protruding aptamers, discernible as discrete regions with a raised height 
profile, to be counted. For DNA origami structures containing aptamer and PfLDH, 1000 nM PfLDH protein was 
incubated with 12 nM DNA origami at room temperature for 1 h, and subsequently visualised under AFM. One 
hundred DNA origami tiles were chosen at random from the existing AFM images and the number of proteins 
immobilised on each tile, discernible as discrete regions with a raised height profile, were evaluated visually. One, 
two and three proteins were countable as discrete structures. Given that the diameter of a single PfLDH allows a 
maximum of four proteins to lie across the width of the DNA origami, protein structures on origami that were 
visible only as a continuous region of raised height were classified as four proteins.
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